| Literature DB >> 27234585 |
Joëlle Dupont1, Rex J Scaramuzzi2.
Abstract
Data derived principally from peripheral tissues (fat, muscle and liver) show that insulin signals via diverse interconnecting intracellular pathways and that some of the major intersecting points (known as critical nodes) are the IRSs (insulin receptor substrates), PI3K (phosphoinositide kinase)/Akt and MAPK (mitogen-activated protein kinase). Most of these insulin pathways are probably also active in the ovary and their ability to interact with each other and also with follicle-stimulating hormone (FSH) and luteinizing hormone (LH) signalling pathways enables insulin to exert direct modulating influences on ovarian function. The present paper reviews the intracellular actions of insulin and the uptake of glucose by ovarian tissues (granulosa, theca and oocyte) during the oestrous/menstrual cycle of some rodent, primate and ruminant species. Insulin signals through diverse pathways and these are discussed with specific reference to follicular cell types (granulosa, theca and oocyte). The signalling pathways for FSH in granulosa cells and LH in granulosa and theca cells are summarized. The roles of glucose and of insulin-mediated uptake of glucose in folliculogenesis are discussed. It is suggested that glucose in addition to its well-established role of providing energy for cellular function may also have insulin-mediated signalling functions in ovarian cells, involving AMPK (AMP-dependent protein kinase) and/or hexosamine. Potential interactions of insulin signalling with FSH or LH signalling at critical nodes are identified and the available evidence for such interactions in ovarian cells is discussed. Finally the action of the insulin-sensitizing drugs metformin and the thiazolidinedione rosiglitazone on follicular cells is reviewed.Entities:
Keywords: Akt; MAPK; corpus luteum; follicle-stimulating hormone (FSH); granulosa; insulin receptor substrate (IRS); luteinizing hormone (LH); metformin; oestradiol; oocyte; progesterone; theca; thiazolidinedione
Mesh:
Substances:
Year: 2016 PMID: 27234585 PMCID: PMC4888492 DOI: 10.1042/BCJ20160124
Source DB: PubMed Journal: Biochem J ISSN: 0264-6021 Impact factor: 3.857
Figure 1Following insulin binding, the IR auto-phosphorylates and then phosphorylates its substrates including the IRSs and Shc
Following phosphorylation, specific domains in these substrates interact with other proteins. One of the major complexes interacting with IRSs is PI3K, which is formed of two interacting proteins: a regulatory subunit (p85) and a catalytic subunit (p110). There are several isoforms of both subunits: p85α, p55α, p50α, p85β and p55γ for the regulatory subunit and p110α, β and δ for the catalytic subunit. The binding of the regulatory subunit to IRS forms an active heterodimer which phosphorylates membrane phosphatidylinositol residues in the 3′ position of PIP3 to form PDK1/2 (shown in blue). In turn, PDK1 phosphorylates (on threonine and serine residues) and thereby activates Akt/PKB (a serine/threonine kinase, with three isoforms). Downstream (orange boxes), Akt phosphorylates several kinases or transcription factors (some examples are shown) involved in most of the major metabolic effects of insulin: (i) glycogen synthesis through GSK3, which is inactivated by phosphorylation. The inactivation of GSK3 leads to the de-phosphorylation and activation of GS and hence to an acceleration of glycogen synthesis, (ii) inhibition of gluconeogenesis by turning off the PEPCK gene through inhibition of FOXO1 function (mainly in liver and adipose tissue), (iii) protein synthesis through mTOR and subsequent activation of p70S6K and 4EBP1 (eukaryotic translation initiation factor 4E-binding protein 1), (iv) the Akt pathway also stimulates cell growth and differentiation (not shown in the figure) and (v) exerts anti-apoptotic effects by phosphorylating the anti-apoptotic protein, Bad. The kinase, PI3K also activates aPKCs (atypical PKCs) (yellow boxes), which in concert with Akt (via AS160) exerts different effects according to the tissue: in muscle and adipocytes they initiate the translocation of intracellular GLUT4 on to the membrane and thereby stimulate glucose transport into the cell. Another important and well-documented signalling pathway is the Ras/ERK pathway (green boxes). The binding of Grb2 (growth factor receptor-bound protein 2) and Sos (son of sevenless) to tyrosine-phosphorylated IRS or Shc can also activate the small GTPase Ras cascade, Raf and ultimately ERK1 and ERK2 (green boxes). When activated, these serine kinases simulate protein synthesis through the activation of p90S6K and activate transcription factors and ultimately cell multiplication and differentiation. Some lipid phosphatases including PTEN and SHIP2 act on PIP3 to decrease or extinguish the insulin signal. Some of the insulin-stimulated serine kinases (aPKC, JNKs, p90RSK, ERKs and S6 kinase) may also exert negative effects on insulin sensitivity. Stimulatory connections are shown in black and inhibitory ones are shown in red.
The physiological and biochemical consequences of targeted disruption or overexpression of components of insulin signalling pathways in ovarian cells
| Component modified | Targeted ovarian cell | Genetic transformation | Physiological and biochemical consequences | Reference |
|---|---|---|---|---|
| IR or IGF-IR | Developing oocytes | Knockout | Fertile and with normal oestrous cycles, oocyte development and maturation, frequency of littering and litter size | [ |
| IR | Theca-interstitial cells | Knockout | No changes in reproductive development or function in lean mice but when fed on a high-fat diet causing obesity, wild-type (WT) mice were infertile and had increased circulating testosterone levels, whereas knockout mice were fertile and had testosterone concentrations comparable to those found in lean mice | [ |
| PTEN | Granulosa | Knockout | Did not affect initiation of follicle growth but increased granulosa cell proliferation, extended the lifespan of luteal cells and enhanced ovulation | [ |
| PTEN | Oocyte (of primordial follicles) | Knockout | Pan-ovarian follicle activation and premature oocyte depletion, primary ovarian insufficiency | [ |
| PTEN | Oocyte (of primary and developed follicles) | Knockout | Unaltered follicular development, ovulation, oocyte maturation and fertility | [ |
| PI3K | Immature oocyte | Constitutively active overexpression | Anovulation, enlarged ovaries, increased survival of immature follicles, formation of follicles containing multiple oocytes | [ |
| TSC1 | Oocyte | Knockout | Primary ovarian insufficiency | [ |
| TSC1 | Granulosa | Knockout | Infertile with pleiotropic effects on follicle recruitment | [ |
| TSC2 | Oocyte | Knockout | Over-activation of the entire pool of primordial follicles, primary ovarian insufficiency | [ |
| PDK1 | Oocyte (of primordial follicles) | Knockout | Gradual loss of ovarian follicles of all classes, but this phenotype can be reversed by simultaneous null mutation of PTEN | [ |
| rpS6 (the only known ribosomal substrate protein of S6K1) | Oocyte (of primordial follicles) | Knockout | Primary ovarian insufficiency | [ |
| Raptor (regulatory-associated protein of mTORC1) | Oocyte (of primordial follicles) | Knockout | Follicular development and fertility not affected, loss of mTORC1 signalling in oocytes triggered compensatory activation of the PI3K signalling, thus maintaining normal follicular development and fertility | [ |
| Rictor (rapamycin-insensitive companion of mTOR, a key component of mTORC2) | Oocyte (of primordial follicles) | Knockout | POF phenotype, massive follicular death, excessive loss of functional ovarian follicles, abnormal gonadal hormone secretion | [ |
| MAPK, also known as ERK | Granulosa and cumulus cells | Knockout | Failed to ovulate and are completely infertile. Necessary for LH-induced oocyte resumption of meiosis, ovulation and luteinization | [ |
The physiological and biochemical consequences of targeted disruption or overexpression of components of insulin signalling pathways in other (non-ovarian) cells
Note: knockout of insulin is lethal 2 days after birth [202] and knockout of the IR is lethal 1 week after birth [199].
| Component | Tissue/cell type | Effect on fertility | Ovarian consequences | Reference |
|---|---|---|---|---|
| IR | Brain neurons | Impaired fertility (50%) | Fewer antral follicles and corpora lutea due to reduced release of LH | [ |
| IRS-1 | All | 70% pregnancy rate | Mildly defective reproductive function | [ |
| IRS-2 | All | Infertile | Reduced LH levels and gonadotropin number, show reduced gonadotropin-stimulated ovulation and markedly reduced numbers of ovarian follicles and corpora lutea | [ |
| IRS-2 | All | Infertile | Reduced follicle size, increased numbers of atretic follicles, as well as impaired oocyte growth and antral cavity development, granulosa cell proliferation defective | [ |
| IRS-2 | CNS and hypothalamus | Fertile | Minimal defects in pituitary and ovarian hormone concentrations, ovarian anatomy and function | [ |
| IRS-3 | All | Fertile | No effects on fertility or embryonic viability | [ |
| IRS-4 | All | 50% pregnancy rate | Null females are less nurturing of their pups | [ |
| FOXO3a | All | A marked age-dependent decline in reproductive fitness and were sterile by 15 weeks of age | Global follicular activation, oocyte death, early depletion of functional follicles and secondary infertility | [ |
| SHB (3Src homology 2 domain-containing adapter protein B) | All | Fertile. Shb−/− embryos cannot be created on a C57Bl/6 background but only on a mixed genetic background. Heterozygotes (Shb+/−) are viable | Defective meiosis I and early embryo development | [ |
| p110δ ( | All | Sub-fertile | Defects in ovarian follicle maturation | [ |
| Akt1 | All | Reduced fertility | Abnormal oestrous cycles, POF, no compensation was observed by Akt2 or Akt3 | [ |
| Akt2 | All | Reduced fertility in aged mice | Aged mice have testosterone concentrations and ovarian cysts with increased numbers of thecal-interstitial cells | [ |
| Akt2 | All | Normal fertility for young mice | ||
| GSK3 isoforms | Fertile | GSK3α or GSK3β did not induce a lethal phenotype. Individual loss of oocyte but no effect on fertility | [ | |
| IGFBP1 | Overexpression in liver | Reduced fertility | Impaired fertilization or implantation, interrupted or prolonged pregnancies with fetal and neonatal death | [ |
Figure 2Some possible sites of cross-talk (critical nodes) between the insulin and FSH signalling pathways in granulosa cells
Insulin signalling through Akt1 and FOXO1 can enhance FSH-stimulated steroidogenesis and, similarly, FSH acting through Akt1 can enhance insulin-stimulated glucose transport leading to increased flux through the hexosamine pathway and to the inhibition of aromatase. Thus insulin can interact with FSH to stimulate P4 and inhibit E2 production. Likewise, FSH acting via mTOR and/or ERK can enhance cell proliferation and protein synthesis, cell proliferation and, acting via Akt1 and FOXO3a, it can inhibit apoptosis. The FSH-stimulated FOXO1 pathway appears to have stage -specific effects in follicles; in small follicles granulosa cell proliferation is stimulated, in antral follicles it is steroidogenesis that is stimulated and, at ovulation, atresia is stimulated in non-ovulatory follicles. Stimulatory connections are shown in black and inhibitory ones are shown in red.
Figure 3Some possible sites of cross-talk (critical nodes) between the insulin and LH signalling pathways in theca cells
Insulin signalling through Akt1 can stimulate PDE to inhibit the degradation of cAMP and so enhance LH-stimulated androgen production; similarly, insulin acting via Akt1 and FOXO1 can enhance LH-stimulated steroidogenesis. Acting via mTOR and/or ERK, LH can enhance cell proliferation and protein synthesis and it can inhibit apoptosis. LH acting directly or via cAMP can enhance insulin stimulation of ERK, whereas, at the same time, LH can stimulate JAK2 which inhibits Shc activation of ERK. The balance of these opposing actions can modulate insulin-stimulated cell proliferation and protein synthesis. Stimulatory connections are shown in black and inhibitory ones are shown in red.
Effects of insulin sensitizers (metformin, rosiglitazone and pioglitazone) in ovarian cells of different species
| Insulin sensitizer | Ovarian cells | Species or cell line | Biological effects | Reference |
|---|---|---|---|---|
| Metformin | Granulosa | Human | Inhibition of basal and insulin-stimulated E2 and aromatase via an ERK-mediated pathway | [ |
| Metformin | Granulosa | Human | Enhancement of insulin-stimulated lactate production at sub-optimal concentrations of insulin | [ |
| Metformin | Granulosa | HGL5 (human) | Improvement of basal cell viability and Akt phosphorylation | [ |
| Metformin | Granulosa | Rat | Reduction in progesterone and oestradiol production | [ |
| Metformin | Granulosa | Cattle | Inhibition of steroidogenesis and MAPK ERK1/2 phosphorylation through AMPK activation | [ |
| Inhibition of IGF-I-stimulated cell growth, protein synthesis, MAPK ERK1/2 and p90RSK phosphorylation through an AMPK-dependent mechanism | [ | |||
| Metformin | Granulosa | Pig | Improved activation of insulin signalling | [ |
| Metformin | Theca-interstitial | Rat | Inhibition of proliferation via an AMPK-dependent mechanism | [ |
| Metformin | Theca | Human | Inhibition of androgen production | [ |
| Metformin | Cumulus oocyte complex | Cattle | Blockage of meiotic progression at the germinal vesicle stage through an activation of AMPK and inhibition of MAPK ERK1/2 | [ |
| Metformin | Follicle | Knockout | Gradual loss of ovarian follicles of all classes, but this phenotype can be reversed by simultaneous null mutation of PTEN | [ |
| Rosiglitazone | Granulosa cells | Sheep | Inhibited granulosa cell proliferation and increased the secretion of P4 | [ |
| Rosiglitazone | Granulosa lutein cells | Human | Stimulated StAR but had no effect on steroidogenic enzymes E2 or P4 | [ |
| Rosiglitazone | Mixed granulosa, theca and stroma cells | Human | Stimulated P4 and IGFBP-1, inhibited E2 and testosterone, abolished insulin-induced stimulation of testosterone and insulin-dependent stimulation of E2 in the presence of FSH and enhanced insulin-induced inhibition of IGFBP-1 | [ |
| Rosiglitazone | Ovarian cells | Pig | Increased P4 secretion and PPARγ expression and 3βHSD activity. Decreased androstendione and testosterone by reducing the expression and activity of CYP17-lyase and 17βHSD (17β-hydroxysteroid dehydrogenase), but no change in E2 secretion and CYP19a1 | [ |
| Rosiglitazone | Oocytes | Mouse | Stimulated AMPK and enhanced resumption of meiosis in oocytes | [ |
| Rosiglitazone and pioglitazone | Diabetic women with PCOS | Improved insulin resistance and hyperandrogenism by an unknown mechanism | [ | |
| Pioglitazone | NCI-H295R cells | Human cell line | Inhibited androgen production by regulating expression of CYP17 and 3βHSD (3β-hydroxysteroid dehydrogenase) | [ |